Molecular Oncology · 2018 · 60 citations · 36 references
MedicineCell BiologyOncologyChemotherapyMolecular OncologyTumor MicroenvironmentCancer Stem Cell BiologyCancer Stem CellsCellular Responses To HypoxiaChemotherapy ResistanceHypoxia AdaptationOvarian CancerCancer Stem-like CellsHypoxia-driven Therapy ResistanceHypoxia-induced ResistanceHypoxia-induced StemnessHypoxia-mediated ResistanceHypoxia-mediated StemnessHypoxic MicroenvironmentTumor Microenvironment Hypoxia
Ovarian cancer stem cells ( OCSC s) are sources of tumor chemoresistance and recurrence. A hypoxic microenvironment contributes to the chemoresistance of cancer stem cells ( CSC s), but the underlying mechanism is not fully understood yet. Here, we show that increased HIF ‐2α expression is associated with enhanced stemness of OCSC s and poor outcomes in ovarian cancer patients. OVCAR ‐3 and CAOV ‐3 sphere‐forming ( OVCAR ‐3 S and CAOV ‐3 S) cells with OCSC ‐like properties showed strong resistance to adriamycin ( ADR ). Hypoxia (1% O 2 ) induced high expression of both HIF ‐1α and especially HIF ‐2α, and increased the resistance of OVCAR ‐3 S and CAOV ‐3 S cells to ADR . Notably, treatment with ADR further increased the expression of HIF ‐2α, but not that of HIF ‐1α. Knockdown of HIF ‐2 α expression substantially attenuated the resistance of OVCAR ‐3 S and CAOV ‐3 S cells to ADR , and the HIF ‐2 α overexpression had the opposite effect. Furthermore, in mouse models xenografted with OCSC s, HIF ‐2 α depletion significantly inhibited tumor growth and sensitized OCSC s to ADR in vivo . Mechanistically, HIF ‐2α directly promotes transcription/expression of BCRP , a gene encoding a transporter protein responsible for pumping drugs (e.g., ADR ) out of cells, which in turn increases drug resistance due to increased drug transportation. Collectively, our studies reveal a novel drug‐resistant mechanism in ovarian cancer by which hypoxia (and ADR treatment)‐induced HIF ‐2α overexpression endows OCSC s with resistance to ADR by promoting BCRP expression and ADR transportation. Therefore, targeting the HIF ‐2α/ BCRP axis holds therapeutic potential for treating drug‐resistant ovarian cancer.
36
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text